RPE65 and Leber congenital amaurosis: Among numerous ongoing clinical trials in gene therapy for IRDs, LuxturnaTM (Voretigene neparvovecryzl; Spark Therapeutics, Philadelphia, PA) is the first treatment approved by the United States Food and Drug Administration, targeting the RPE65-associated LCA cases46.